Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 study of AOC 1020 in adults with facioscapulohumeral muscular dystrophy
NL-OMON60672Phase 2Completed
- Sponsor
- Avidity Biosciences
- Start
- Jul 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of delpacibart braxlosiran in facioscapulohumeral muscular dystrophy (FSHD), sponsored by Avidity Biosciences. Primary endpoint: Incidence of treatment-emergent adverse events. Started Jul 2023; status: completed.
02
Drugs
delpacibart braxlosiran
03
Conditions
facioscapulohumeral muscular dystrophy (FSHD)
Beyond the preview
Go deeper on NL-OMON60672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60672.